Patents Examined by M. Franco Salvoza
-
Patent number: 9719070Abstract: Methods are described for predicting ancestral sequences for viruses or portions thereof. Also described are predicted ancestral sequences for adeno-associated virus (AAV) capsid polypeptides. The disclosure also provides methods of gene transfer and methods of vaccinating subjects by administering a target antigen operably linked to the AAV capsid polypeptides.Type: GrantFiled: October 12, 2016Date of Patent: August 1, 2017Assignees: Massachusetts Eye and Ear Infirmary, Schepens Eye Research InstituteInventors: Luk H. Vandenberghe, Eric Zinn
-
Patent number: 9713639Abstract: The present invention encompasses porcine epidemic diarrhea virus (PEDV) vaccines or compositions. The vaccine or composition may be a vaccine or composition containing PEDV antigens. The invention also encompasses recombinant vectors encoding and expressing PEDV antigens, epitopes or immunogens which can be used to protect porcine animals against PEDV.Type: GrantFiled: May 19, 2015Date of Patent: July 25, 2017Assignee: MERIAL, INC.Inventors: Paulraj Lawrence, Russell Bey
-
Patent number: 9700588Abstract: Described is the use of a parvovirus, preferably H-1PV, for the therapeutical elimination of cancer stem cells (CSCs), preferably neuroblastoma stem cells and glioblastoma stem cells.Type: GrantFiled: June 29, 2011Date of Patent: July 11, 2017Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERSITAET HEIDELBERGInventors: Jean Rommelaere, Jeannine Lacroix, Joerg Schlehofer, Olaf Witt, Elisabeth Hedwig Deubzer, Sonja Kern, Christel Herold-Mende, Karsten Geletneky, Barbara Leuchs
-
Patent number: 9695220Abstract: Methods are described for predicting ancestral sequences for viruses or portions thereof. Also described are predicted ancestral sequences for adeno-associated virus (AAV) capsid polypeptides. The disclosure also provides methods of gene transfer and methods of vaccinating subjects by administering a target antigen operably linked to the AAV capsid polypeptides.Type: GrantFiled: April 11, 2016Date of Patent: July 4, 2017Assignees: Massachusetts Eye & Ear Infirmary, Schepens Eye Research InstituteInventors: Luk H. Vandenberghe, Eric Zinn
-
Patent number: 9682133Abstract: The invention is directed to an adenovirus-antigen conjugate comprising (a) a disrupted adenovirus with a coat protein and (b) an antigen conjugated to the coat protein of the disrupted adenovirus, as well as a conjugate comprising (a) a disrupted adenovirus with a coat protein and (b) an antigen conjugated to the coat protein of the disrupted adenovirus. The invention also provides a method of inducing an immune response against an antigen in a human using the aforementioned conjugates. The invention further provides an adeno-associated viral vector comprising a nucleic acid sequence which encodes an antibody directed against cocaine.Type: GrantFiled: March 17, 2011Date of Patent: June 20, 2017Assignee: CORNELL UNIVERSITYInventors: Ronald G. Crystal, Bishnu De, Martin Hicks, Jonathan Rosenberg, Stephen M. Kaminsky
-
Patent number: 9676827Abstract: A fusion protein for use as an immunogen enhancer for enhancing antigen-specific T cell responses is disclosed. The fusion protein comprises: (a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain; (b) a protein transduction domain; and (c) an antigen of a pathogen, wherein the APC-binding domain or the CD91 receptor-binding domain is located at the N-terminus of the fusion protein, and the antigen of the pathogen is located at the C-terminus of the protein transduction domain. The protein transduction domain is selected from the group consisting of: (i) a fusion polypeptide, comprising a T cell sensitizing signal-transducing peptide, a linker, and a translocation peptide; (ii) a T cell-sensitizing signal-transducing peptide; and (iii) a translocation peptide of 34-112 amino acid residues in length.Type: GrantFiled: September 22, 2016Date of Patent: June 13, 2017Assignee: TheVax Genetics Vaccine Co., Ltd.Inventors: Chia-Mao Wu, Hsiu-Kang Chang
-
Patent number: 9675687Abstract: Polyvalent, primary isolate nucleic acid compositions for inducing an immune response against HIV are disclosed. The compositions and methods described herein are for the use of a nucleic acid composition that encodes one or more different HIV envelope glycoproteins. The synthetic, codon-optimized DNAs encoding one or more HIV proteins are a combination of different nucleic acids, such as DNA plasmids, generated from primary isolate DNA of different HIV major group genetic clades and/or different proteins. HIV polypeptide compositions for inducing an immune response against HIV are also disclosed. Methods for using the polypeptide compositions before, at the same time as, and/or after administration of the DNA compositions are provided.Type: GrantFiled: March 13, 2014Date of Patent: June 13, 2017Assignee: University of MassachusettsInventors: Shan Lu, Shixia Wang
-
Patent number: 9658224Abstract: The present invention relates to novel methods for detecting a member of a known binding pair in a sample, including a cell, where one member of the pair (termed the “receptor”) is expressed by a bacteriophage, which phage is then used to detect the presence of the other member of the pair (termed the “ligand” or “target”). Rather than detecting the binding of the phage using antibody-based technology, the present invention relates to detecting marker molecule associated with the phage. In one aspect, the invention relates to identifying an antigen-bearing moiety (e.g., a red blood cell antigen) of interest present on a cell, e.g., a red blood cell, using antibody-displaying bacteriophage, as well as detecting anti-red blood cell auto- or alloantibodies and/or complement in a sample, using antiglobulin reagent-displaying bacteriophage and detecting a marker molecule associated with the phage. In one aspect, the phenotype of the phage is not linked with the genotype of the phage.Type: GrantFiled: November 14, 2006Date of Patent: May 23, 2017Assignees: The Trustees of the University of Pennsylvania, The Scripps Research InsituteInventors: Donald Siegel, Carlos F. Barbas, III
-
Patent number: 9657310Abstract: Disclosed are a novel expression vector for efficient expression of recombinant proteins in mammalian cells, a mammalian cell transformed with the vector, and a method for production of the mammalian cell. The expression vector is an expression vector for expression of a mammalian protein and includes a gene expression regulatory site, and a gene encoding the protein downstream thereof, and an internal ribosome entry site further downstream thereof, and a gene encoding a glutamine synthetase further downstream thereof, and a dihydrofolate reductase gene downstream of either the same gene expression regulatory site or another gene expression regulatory site in addition to the former.Type: GrantFiled: April 25, 2013Date of Patent: May 23, 2017Assignee: JCR PHARMACEUTICALS CO., LTD.Inventors: Kenichi Takahashi, Shinji Kakimoto
-
Patent number: 9650424Abstract: Provided in the embodiments of the present invention is a vaccine composition including an immune amount of attenuated live vaccine, inactivated vaccine, subunit vaccine, synthetic vaccine, or genetically engineered vaccine of the porcine pseudorabies virus strain. The vaccine composition can effectively induce antibody generation, and prevent infections of virulent strains of the porcine pseudorabies virus, and provides effective protection for pigs.Type: GrantFiled: December 28, 2015Date of Patent: May 16, 2017Assignee: PULIKE BIOLOGICAL ENGINEERING, INC.Inventors: Xuke Zhang, Jinzhong Sun, Rui Wu, Feifei Tan, Chaoyong Bai, Kegong Tian
-
Patent number: 9638692Abstract: The present invention provides kits and assay methods for the early detection of pathogens, precise identification of the etiologic agent, and improved disease surveillance. More specifically, the present invention discloses an immunoassay leading to the rapid and simultaneous detection of antibodies to a wide range of infectious pathogens in biological fluids of infected patients. This immunoassay involves the covalent and oriented coupling of fusion proteins comprising an AGT enzyme and a viral antigen on an identifiable solid support (e.g. fluorescent microspheres), said support being previously coated with an AGT substrate. This coupling is mediated by the irreversible reaction of the AGT enzyme on its substrate. The thus obtained antigen-coupled microspheres show enhanced capture of specific antibodies as compared to antigen-coupled microspheres produced by standard amine coupling procedures.Type: GrantFiled: December 10, 2012Date of Patent: May 2, 2017Assignee: INSTITUT PASTEURInventors: Jean-Claude Manuguerra, Jessica Vanhomwegen, Philippe Despres, Sylvie Paulous
-
Patent number: 9623095Abstract: The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.Type: GrantFiled: February 29, 2012Date of Patent: April 18, 2017Assignee: CureVac AGInventors: Karl-Josef Kallen, Thomas Kramps, Margit Schnee, Benjamin Petsch, Lothar Stitz
-
Patent number: 9611301Abstract: GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving GBV-C E2 polypeptides and peptides for use in modulating immune responses, including inhibition inflammation related to pathogenic T-cell activation.Type: GrantFiled: March 13, 2013Date of Patent: April 4, 2017Assignees: The University of Iowa Research Foundation, The United States of America as Represented by The Department of Veterans AffairsInventors: Jack T. Stapleton, Nirjal Bhattarai, Jinhua Xiang, James H. McLinden
-
Patent number: 9598470Abstract: The present invention relates to compositions and methods comprising chemopreventive agents that may be cupredoxin(s) or variants, derivatives and structural equivalents of cupredoxins, and at least one other chemopreventive agent. Specifically, these compositions may comprise azurin from Pseudomonas aeruginosa, and/or the 50-77 residue region of azurin (p28). The compositions of the invention may be used to prevent or inhibit the development of premalignant lesions in mammalian cells, tissues and animals, and thus prevent cancer.Type: GrantFiled: May 18, 2009Date of Patent: March 21, 2017Inventors: Craig W. Beattie, Tohru Yamada, Tapas K. Das Gupta
-
Patent number: 9587025Abstract: This invention concerns anti-inflammatory agents, compositions, and methods for treating inflammatory disorders.Type: GrantFiled: December 10, 2012Date of Patent: March 7, 2017Assignee: The Rockefeller UniversityInventors: Jeffrey V. Ravetch, Andrew Pincetic
-
Patent number: 9567375Abstract: The present invention relates to chimeric pestiviruses having utility as immunogenic compositions and vaccines. Also described herein are methods and kits for treating or preventing the spread of bovine viral diarrhea virus infection, as well as methods and kits for differentiating between vaccinated and wild-type infected animals.Type: GrantFiled: November 24, 2009Date of Patent: February 14, 2017Assignee: Zoetis Services LLCInventors: Yugang Luo, Siao-Kun Wan Welch, Ying Yuan, Robert Gerard Ankenbauer
-
Patent number: 9561270Abstract: The present invention provides methods of reducing the virucidal activity of a composition comprising a PCV-2 antigen as well as antigenic preparations and immunogenic compositions comprising a PCV-2 antigen, wherein the virucidal activity has been reduced. In addition, the present invention also relates to a method of increasing the immunogenicity of an immunogenic composition comprising a PCV-2 antigen as well as immunogenic composition with an increased immunogenicity.Type: GrantFiled: September 2, 2010Date of Patent: February 7, 2017Assignee: Boehringer Ingelheim Vetmedica, Inc.Inventors: Caroline Ann Kohler, Guosong Zhao, Ali Khazraeinazmpour, Bernd Colin Eichenmueller, Marc Allan Eichmeyer, Gregory Haiwick, Merrill Lynn Schaeffer
-
Patent number: 9549976Abstract: The invention relates to virus-like particles of bacteriophage MS2 (MS2 VLPs) displaying peptide epitopes or peptide mimics of epitopes of Nipah Virus envelope glycoprotein that elicit an immune response against Nipah Virus upon vaccination of humans or animals. Affinity selection on Nipah Virus-neutralizing monoclonal antibodies using random sequence peptide libraries on MS2 VLPs selected peptides with sequence similarity to peptide sequences found within the envelope glycoprotein of Nipah itself, thus identifying the epitopes the antibodies recognize. The selected peptide sequences themselves are not necessarily identical in all respects to a sequence within Nipah Virus glycoprotein, and therefore may be referred to as epitope mimics VLPs displaying these epitope mimics can serve as vaccine. On the other hand, display of the corresponding wild-type sequence derived from Nipah Virus and corresponding to the epitope mapped by affinity selection, may also be used as a vaccine.Type: GrantFiled: November 15, 2013Date of Patent: January 24, 2017Assignees: STC.UNM, SANDIA CORPORATIONInventors: David S. Peabody, Bryce Chackerian, Carlee Ashley, Eric Carnes, Oscar Negrete
-
Patent number: 9546112Abstract: Methods for increasing the efficiency of target tissue penetration of an adeno-associated virus (AAV) vector in a patient are provided. In some aspects, the methods involve inhibiting the interaction of the serum protein galectin 3 binding protein (G3BP) with AAV vector. Further provided are methods for reducing tissue distribution of a virus or for neutralizing a virus harbored by an organ destined for transplant, or newly transplanted, by administering a composition comprising G3BP.Type: GrantFiled: March 22, 2011Date of Patent: January 17, 2017Assignees: ASSOCIATION INSTITUT DE MYOLOGIE, GÉNÉTHON, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ PIERRE ET MARIE CURIE (PARIS 6), INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALEInventors: Thomas Voit, Luis Garcia, Jérôme Denard, Fedor Svinartchouk
-
Patent number: 9518303Abstract: Certain embodiments of the invention include, but are not limited to PCR primer pairs, sequencing primers, and/or associated thermocycling protocols targeting a region identified by the inventors within the 5? untranslated region of enteroviruses for the purpose of identifying, subtyping, and/or classifying of virus in samples using nucleic acid sequencing. The sequencing procedures can use nucleic acid templates, such as cDNA or PCR amplicons, as a template for sequencing in medium to high throughput format that is cost effective and easily deployed to other clinical microbiology laboratories.Type: GrantFiled: October 25, 2012Date of Patent: December 13, 2016Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: Richard B. Pyles, Aaron L. Miller